Business Wire

LECLANCHÉ-&-KONGSBERG

12.11.2018 07:32:12 CET | Business Wire | Press release

Share
Leclanché Selected by KONGSBERG to Power the Fast Growing Electric and Hybrid Marine Industry with Energy Storage Solutions

Leading global maritime technology company Kongsberg Maritime has selected Leclanché, one of the world’s leading storage solutions companies, as its battery partner and supplier of customised marine energy storage solutions. The partnership contributes to KONGSBERG’s new generation of hybrid power solutions, which are set to deliver game-changing efficiencies and reduce the environmental impact of transportation with cutting-edge autonomous and crewed vessel newbuilds.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181111005050/en/

Leclanché’s batteries will be an integral part of KONGBSERG’s hybrid solutions. Through the partnership, Leclanché will deliver one of the largest single marine battery system order to date for 9 vessels totalling 45MWh batteries. The systems will be built at Leclanché’s facility in Switzerland with the cells manufactured at Leclanché’s Willstätt facility in Germany.

  • The first project to be jointly executed will be Yara Birkeland, the world’s first autonomous and electric container vessel with zero emissions ordered by YARA, one of the world’s leading fertilizer companies and a provider of environmental solutions. Replacing 40,000 truck journeys a year, Yara Birkeland will eliminate NOx and CO2 emissions and improve road safety, whilst also reducing noise and dust emissions currently caused by trucks in a densely populated urban area. https://www.youtube.com/watch?v=tFH595gytSE
  • The second project relates to vessels known as Grimaldi Green 5th Generation (GG5G). Grimaldi is one of the world’s largest operators of Roll-on/ Roll-off (Ro-Ro) and Roll-on/ Roll-off Passenger (Ro-Pax) vessels. The hybrid propulsion system delivered by Kongsberg includes supply and integration of shaft generators, frequency drives, energy management systems together with Leclanché battery systems. The GG5Gs will be the first in a new series of hybrid Ro-Ro vessels using fossil fuel during navigation, with batteries providing a peak-shaving function and electricity in port.

The new partnership with KONGSBERG underscores Leclanché’s strategy of being a vertically integrated system supplier to growth markets such as merchant marine and fleet transportation, moving beyond being a ‘pure play’ cell producer. Leclanché made an early investment in developing a DNV GL certified battery system for marine applications, and is the first battery supplier to fully comply with the stringent 2015 regulations that are currently in force. DNV GL is an international accredited registrar and classification society for maritime vessels headquartered in Høvik, Norway.

Frode Kaland, EVP Supply Chain for Kongsberg Maritime said: “Leclanché’s ability to cover the complete value chain from design and production of lithium cells in Europe, to full battery systems certified for marine applications together with our proprietary hybrid power technology positions us together as a single, unified supplier of electrification solutions that will deliver lower operational expenditure and enable environmental sustainability for all vessel types” .

Anil Srivastava, CEO of Leclanché said: "The partnership between Kongsberg Maritime, one of the world’s leading providers of electrification solutions to the maritime industry and Leclanché has the potential to be game changing as it brings low and zero-emission solutions to the sizeable and fast growing electric and hybrid marine market. Leclanché’s focus on maritime is an essential component of our focus on the electrification of fleets and maritime is ideally suited to both our superior battery systems and our partnership approach to deliver emissions busting solutions. We are seeing a paradigm shift in the maritime industry towards electric power and partnerships with world class industry leaders such as KONGSBERG further demonstrate that Leclanché’s opportunity is now."

* * * * *

About Kongsberg

KONGSBERG (OSE-ticker: KOG) is an international, knowledge-based group delivering high technology systems and solutions to clients within the oil and gas industry, merchant marine, defence and aerospace. KONGSBERG has 7 000 employees located in more than 25 countries and total revenues of NOK 14.5 billion in 2017. Follow us on Twitter: @kongsbergasa. kongsberg.com

Kongsberg Maritime (KM) is the largest division of KONGSBERG and a world-leader in the development and delivery of integrated vessel concepts for traditional merchant vessels and fishing vessels, as well as offshore and research vessels and offshore installations.

The maritime industry is entering a new era, and Kongsberg Maritime is at the forefront of these changes.

About Leclanché

Headquartered in Switzerland, Leclanché SA is a leading provider of high quality energy storage solutions designed to accelerate our progress towards a clean energy future. Leclanché’s history and heritage is rooted in over 100 years of battery and energy storage innovation and the Company is a trusted provider of energy storage solutions globally. This coupled with the Company’s culture of German engineering and Swiss precision and quality, continues to make Leclanché the partner of choice for both disruptors, established companies and governments who are pioneering positive changes in how energy is produced, distributed and consumed around the world. The energy transition is being driven primarily by changes in the management of our electricity networks and the electrification of transport, and these two end markets form the backbone of our strategy and business model. Leclanché is at the heart of the convergence of the electrification of transport and the changes in the distribution network. Leclanché is the only listed pure play energy storage company in the world, organised along three business units: stationary storage solutions, etransport solutions and specialty batteries systems. Leclanché is listed on the Swiss Stock Exchange (SIX: LECN). Leclanche.com

SIX Swiss Exchange: ticker symbol LECN | ISIN CH 011 030 311 9

Disclaimer

This press release contains certain forward-looking statements relating to Leclanché's business, which can be identified by terminology such as "strategic", "proposes", "to introduce", "will", "planned", "expected", "commitment", "expects", "set", "preparing", "plans", "estimates", "aims", "would", "potential", "awaiting", "estimated", "proposal", or similar expressions, or by expressed or implied discussions regarding the ramp up of Leclanché's production capacity, potential applications for existing products, or regarding potential future revenues from any such products, or potential future sales or earnings of Leclanché or any of its business units.

You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of Leclanché regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Leclanché's products will achieve any particular revenue levels. Nor can there be any guarantee that Leclanché, or any of the business units, will achieve any particular financial results.

* * * * *

Contact:

Kongsberg contact : Gunvor Hatling Midtbø T : + 47 99214209 E-mail : ghm@konsgberg.com or Leclanché contacts Media contacts Europe/global : Desiree Maghoo T : +44 (0) 7775 522 740 E-mail : dmaghoo@questorconsulting.com or Thomas Balmer T : +41 (0) 79 703 87 28 E-mail : tba@dynamicsgroup.ch or Laure Lagrange T : +44 (0) 7768 698 731 E-mail : llagrange@questorconsulting.com or US and Canada : Rick Anderson T : +1-718-986-1596 or Henry Feintuch T : +1-212-808-4901 E-mail: Leclanché@feintuchpr.com Switzerland : Thierry Meyer T : +41 (0) 79 785 35 81 E-mail : tme@dynamicsgroup.ch or Investor Contacts : Anil Srivastava / Hubert Angleys T : +41 (0) 24 424 65 00 E-mail : invest.Leclanché@Leclanché.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye